HIV-indeterminate Western blotting (WB) results are typically obtained in WB confirmatory assays, and the number of indeterminate samples may increase with the detection of HIV infections, which will present considerable challenges for the management of HIV/AIDS. Nucleic acid detection has been used as a laboratory test for screening suspected or indeterminate samples. However, the effectiveness of these assays for the differential diagnosis of HIV-indeterminate WB samples remained undetermined. In this study, 210 subjects with HIV-indeterminate WB results were detected from 6360 positive HIV screening samples between 2015 and 2016 in southeastern China, in which HIV-indeterminate WB results accounted for 3.30%. The highest proportion of indeterminate results was observed in pregnant and lying-in women receiving physical examinations (16.67%), followed by that in voluntary blood donors (8.82%). The most common WB band patterns were p24, gp160 and p24, and gp160. The follow-up study revealed that the highest negative and positive conversion rates of HIV antibodies were in samples with a single p24 band (80.28%), and with gp160 and p24 bands (86.21%), respectively. Among the Env, Gag, and Pol antibodies, samples with a Gag band showed the highest negative conversion rate (81.25%), whereas the highest positive conversion rate was observed in samples with an Env band (56.76%). In addition, quantitative and qualitative HIV nucleic acid testing exhibited the highest sensitivity (96.3%) and specificity (97.85%), respectively. Our results indicate a lower proportion of HIV indeterminate WB results in southeastern China compared to previous reports, and the follow-up re-examination of patients with HIV indeterminate results should be performed. Nucleic acid testing facilitates the identification of HIV infections.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687788 | PMC |
http://dx.doi.org/10.1007/s12250-019-00130-3 | DOI Listing |
Cureus
October 2024
Pulmonary and Critical Care Medicine, St. Michael's Medical Center, Newark, USA.
Epidermal growth factor receptor (EGFR) inhibitors have largely been used for head and neck cancers, non-small cell lung cancers, and colorectal cancers (CRC). Reports of interstitial pneumonitis with EGFR inhibitors like gefitinib and erlotinib are present in the literature, but pulmonary toxicity with cetuximab has rarely been reported. We present a case of a 78-year-old male with metastatic CRC involving the brain and lungs who presented with severe pneumonitis, a month after treatment with cetuximab.
View Article and Find Full Text PDFRev Med Inst Mex Seguro Soc
February 2024
Instituto Politécnico Nacional, Escuela Nacional de Ciencias Biológicas. Ciudad de México, México.
AIDS
November 2024
Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, NSW, Australia.
Objective: Data on the impact of COVID-19 in people living with HIV (PWH) are lacking in resource-constrained settings. We utilised existingrandomised clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a SARS-CoV-2 serosurvey, between January and March 2021, while characterising participants' features.
Design: Cross-sectional serosurvey.
Sci Rep
November 2024
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Architect-HIV Ag/Ab combo chemiluminescence assay is globally recognized for its sensitivity but has a notable false-positive rate. In this study, we aim to evaluate the performance of a new cost-effective screening alternative, the chemiluminescence Ag/Ab combo assay (CL-900i-HIV) from Mindray, China. We selected 195 archived samples categorized according to the INNO-LIA™ HIV I/II, the gold standard confirmatory assay.
View Article and Find Full Text PDFFront Mol Med
January 2024
School of Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Durban, Kwazulu-Natal, South Africa.
Accurate diagnosis of latent tuberculosis infected (LTBI) individuals is important in identifying individuals at risk of developing active tuberculosis. Current diagnosis of LTBI routinely relies on the detection and measurement of immune responses using the Tuberculin Skin Test (TST) and interferon gamma release assays (IGRAs). However, IGRA, which detects specific IFN-γ, is associated with frequent indeterminate results, particularly in immunosuppressed patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!